Recommendations from this review for the implementation of routine clinical detection of RET fusion genes and RET mutations in thyroid malignancies include the use of FISH or real-time PCR in tumours where RET fusions or mutations are highly prevalent, and in cancers that are rarely RET rearranged, broad panel assays that query RET fusions can be used to allow screening in a histotype-agnostic manner (29). This evidence concerns the gene RET and cancer.